-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (DTRMWXHS-12 + Everolimus + Pomalidomide) in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (DTRMWXHS-12 + Everolimus + Pomalidomide) in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (DTRMWXHS-12 + Everolimus + Pomalidomide) in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (DTRMWXHS-12 + Everolimus + Pomalidomide) in Follicular Lymphoma...
-
Product Insights
Myotonic Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Myotonic Dystrophy - Drugs In Development, 2023’, provides an overview of the Myotonic Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myotonic Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Spinocerebellar Ataxia (SCA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinocerebellar Ataxia (SCA) - Drugs In Development, 2023’, provides an overview of the Spinocerebellar Ataxia (SCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (DTRMWXHS-12 + everolimus + pomalidomide) in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (DTRMWXHS-12 + everolimus + pomalidomide) in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Dtrmwxhs-12 + Everolimus + Pomalidomide) in Diffuse...
-
Company Profile
Kodiak Sciences Inc – Company Profile
Kodiak Sciences Inc (Kodiak Sciences) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of chronic and high-prevalence ophthalmic diseases. The company pipeline products includes KSI 301 an anti-VEGF biologic development, which offers wet AMD, diabetic macular edema, retinal vein occlusion and diabetic retinopathy; KSI-501 an anti-IL6 and anti-VEGF bispecific biopolymer conjugate; and KSI-601 a triplet biopolymer conjugate, which treats dry age-related macular degeneration. Kodiak Sciences utilizes proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, that combines biologics design with...
Add to Basket -
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...